U.S. NEUROPATHIC PAIN TREATMENT MARKET ANALYSIS

U.S. Neuropathic Pain Treatment Market, by Drug Type (Pain Relievers (NSAIDS, Opioids (Tramadol, Oxycodone, and Others)), Anti-seizure Medications (Gabapentin, Pregabalin, and Others), Topical Treatments, Antidepressants (Duloxetine, Amitriptyline, Escitalopram, and Others), and Others), by Indication (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022
Code : CMI5429
Pages :155
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

Side effects associated with the treatment of neuropathic pain

U.S. Neuropathic Pain Treatment Market- Restraint

Side effects associated with peripheral neuropathy medication will hamper the growth of U.S. neuropathic pain treatment market over the forecast period. For instance, the most common side effects with peripheral neuropathy medication include tiredness, dizziness or feeling drunk, feeling sick or vomiting, weight gain, constipation, etc. Moreover, some side effects can be serious which include hives, rash, blisters, hoarseness, difficulty swallowing or breathing, changes in heartbeat, loss of consciousness, and others

U.S. Neuropathic Pain Treatment Market- Key Drivers

The increasing prevalence of chronic diseases such as cancer, heart diseases, etc. is expected to drive the U.S. neuropathic pain treatment market growth over the forecast period, For instance, according to an article published by PubMed in January 2021, around 1,898,160 new cancer cases and 608,570 cancer deaths were estimated to be reported in the U.S. in 2021. Furthermore, according to data published by HIV.gov in September 2022, around 1.2 million people in the U.S. have HIV.